119th Congress
H.R. 8857
Next GEN Act of 2026
- Introduced
- In committee
- Passed House
- Passed Senate
- To President
- Became law
- Sponsor
- Joseph D. Morelle(D-NY)
- Introduced
- May 15, 2026
- Policy area
- Health
- Committees
- House Committee on Energy and Commerce; House Committee on Ways and Means
- Official text
- Introduced in House · Congress.gov page
Cosponsors (4)
Original cosponsors (3)
- August Pfluger (R-TX)
- Josh Gottheimer (D-NJ)
- Thomas H. Kean, Jr. (R-NJ)
Added later (1)
- Donald G. Davis (D-NC) · Aug 27, 2026
Summary
No Congressional Research Service summary yet. CRS usually publishes one a few weeks after a bill is introduced.
Official title: To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.
Latest action(May 15, 2026): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Roll-call votes
No recorded votes on this bill.
Actions
- May 15, 2026 · House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. - May 15, 2026
Introduced in House